Search Results

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.

• Authors : Ochoge, Magnus (AUTHOR); Futa, Ahmed Cherno (AUTHOR); Umesi, Ama (AUTHOR)

Subjects: BILL & Melinda Gates Foundation; ORAL vaccines; INFANTSGAMBIA

• Source: Lancet. Mar2024, Vol. 403 Issue 10432, p1164-1175. 12p.

Record details

Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.

Subjects: COVID-19; COVID-19 pandemic; COVID-19 vaccinesNORTHERN Ireland; WALES; SCOTLAND

• Source: Lancet. Feb2024, Vol. 403 Issue 10426, p554-566. 13p.

Record details

Effects of a SARS-associated coronavirus vaccine in monkeys.

Subjects: *VACCINATION; *SARS disease; *RHESUS monkeys

• Source: Lancet. 12/6/2003, Vol. 362 Issue 9399, p1895-1895. 2p. 1 Black and White Photograph, 2 Graphs.

Record details

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.

• Authors : Ella, Raches (AUTHOR); Reddy, Siddarth (AUTHOR); Blackwelder, William (AUTHOR)

Subjects: SARS-CoV-2; COVID-19; VACCINATION complications

• Source: Lancet. Dec2021, Vol. 398 Issue 10317, p2173-2184. 12p.

Record details

Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.

• Authors : Sonabend, Raphael (AUTHOR); Whittles, Lilith K (AUTHOR); Imai, Natsuko (AUTHOR)

Subjects: SARS-CoV-2; STAY-at-home orders; VACCINE effectivenessENGLAND; UNITED Kingdom

• Source: Lancet. Nov2021, Vol. 398 Issue 10313, p1825-1835. 11p.

Record details

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.

• Authors : Haas, Eric J (AUTHOR); Angulo, Frederick J (AUTHOR); McLaughlin, John M (AUTHOR)

Subjects: COVID-19; COVID-19 pandemic; SARS-CoV-2ISRAEL

• Source: Lancet. 5/15/2021, Vol. 397 Issue 10287, p1819-1829. 11p.

Record details

COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges.

• Authors : Phelan, Alexandra L (AUTHOR)

Subjects: COVID-19; PASSPORTS; POLIO

• Source: Lancet. 5/23/2020, Vol. 395 Issue 10237, p1595-1598. 4p.

Record details

Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.

• Authors : Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members (CORPORATE AUTHOR)

Subjects: COVID-19 vaccines; LOW-income countries; MIDDLE-income countries

• Source: Lancet. 2/13/2021, Vol. 397 Issue 10274, p562-564. 3p.

Record details

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

• Authors : Lin, Jiangtao; Zhang, Jiansan; Dong, Xiaoping

Subjects: CLINICAL trials; VACCINATION; PREVENTIVE medicine

• Source: Lancet. 9/16/2006, Vol. 368 Issue 9540, p991-997. 7p. 4 Charts, 2 Graphs.

Record details

Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial.

• Authors : Greenberg, Richard N.; Kennedy, Jeffrey S.; Clanton, David J.

Subjects: VACCINATION; VACCINIA; SMALLPOX vaccines

• Source: Lancet. 1/29/2005, Vol. 365 Issue 9457, p398-409. 12p. 1 Diagram, 5 Charts, 9 Graphs.

Record details